- Home
- KLAR vs IQV Comparison
KLAR vs IQV Comparison
Compare KLAR & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLAR
- IQV
- Stock Information
- Founded
- KLAR 2005
- IQV 1982
- Country
- KLAR United Kingdom
- IQV United States
- Employees
- KLAR N/A
- IQV N/A
- Industry
- KLAR Finance: Consumer Services
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- KLAR Finance
- IQV Health Care
- Exchange
- KLAR Nasdaq
- IQV Nasdaq
- Market Cap
- KLAR 30.9B
- IQV 31.0B
- IPO Year
- KLAR 2025
- IQV 2013
- Fundamental
- Price
- KLAR N/A
- IQV $186.72
- Analyst Decision
- KLAR Buy
- IQV Strong Buy
- Analyst Count
- KLAR 2
- IQV 20
- Target Price
- KLAR $53.00
- IQV $229.15
- AVG Volume (30 Days)
- KLAR 16.8M
- IQV 1.2M
- Earning Date
- KLAR 01-01-0001
- IQV 10-30-2025
- Dividend Yield
- KLAR N/A
- IQV N/A
- EPS Growth
- KLAR N/A
- IQV N/A
- EPS
- KLAR N/A
- IQV 6.92
- Revenue
- KLAR $3,009,058,798.00
- IQV $15,700,000,000.00
- Revenue This Year
- KLAR N/A
- IQV $6.01
- Revenue Next Year
- KLAR N/A
- IQV $5.05
- P/E Ratio
- KLAR N/A
- IQV $27.06
- Revenue Growth
- KLAR 19.78
- IQV 3.60
- 52 Week Low
- KLAR $40.25
- IQV $134.65
- 52 Week High
- KLAR $57.20
- IQV $248.03
- Technical
- Relative Strength Index (RSI)
- KLAR N/A
- IQV 51.04
- Support Level
- KLAR N/A
- IQV $183.10
- Resistance Level
- KLAR N/A
- IQV $191.86
- Average True Range (ATR)
- KLAR 0.00
- IQV 4.74
- MACD
- KLAR 0.00
- IQV -0.61
- Stochastic Oscillator
- KLAR 0.00
- IQV 62.20
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.